Latest News & Features
Big Pharma
The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears. 19 February 2014
article
It’s been a long time coming, but perhaps the Brazilian patent office is finally going to deal with the logjam of patent applications, says Gabriel di Blasi. 19 February 2014
Biotechnology
Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains. 19 February 2014
Americas
The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen. 19 February 2014
article
The rise of so-called personalised medicine presents new challenges and opportunities for drugs companies, says Robert Andrews. 19 February 2014
Genetics
An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions. 19 February 2014
Big Pharma
Several of the world’s 10 top-selling drugs lose exclusivity this year. LSIPR takes a look at the products, their major competitors, and their manufacturers’ strategies for keeping a grasp of market share. 19 February 2014
Americas
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level. 3 February 2014
article
Susana Soares is a designer inspired by scientific research to create objects that explore new aesthetic and behavioural opportunities. LSIPR investigated how she protects her work in a realm where life sciences and design collide. 3 February 2014
Americas
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field. 13 January 2014